MARKET WIREYahoo • 3d ago
ClearPoint Neuro, Inc. Q3 2026 Earnings Call SummaryMoby summary of ClearPoint Neuro, Inc.'s Q3 2026 earnings call
Why CLPT Stock advanced +1.23% Today — RQD Quant Desk Flash
$10.69 +1.23% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $10.69
ClearPoint Neuro Inc. (CLPT) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $342.7M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $10.69 (+0.03%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLPT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY CLPT SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (38% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)
FRED Regime × Technicals: 21% of 52W Range • RSI-14 at 48.9 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$10.48-13.5% Next Q
26
Q2 (-2Q)Grade E$9.07+0.8% Next Q
29
Q3 (-1Q)Grade E$9.14+17% Next Q
31
CurrentGrade E$10.69-8.7% Hist 90D α
34
Trajectory: E (26) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CLPT Turnaround Squeeze
While CLPT currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.51) and Max Pain ($11.22) forces dealer call-delta covering toward $20.66.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLPT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CLPT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CLPT Stock advanced +1.23% Today — RQD Quant Desk Flash
ClearPoint Neuro Inc. (CLPT) advanced +1.23% to $10.69, trading at 21% of its 52-week range ($8.27 – $19.68). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 21% of its 52-week range ($8.27 – $19.68) with RSI-14 at 48.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $10.69 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 61.4% gross margin and $0 annual free cash flow.
Live CLPT Headlines & Catalysts
MARKET WIREBenzinga • 3d ago
Stifel Maintains Buy on ClearPoint Neuro, Lowers Price Target to $18Stifel analyst Mathew Blackman maintains ClearPoint Neuro (NASDAQ:CLPT) with a Buy and lowers the price target from $22 to $18.
CATALYSTYahoo • 3d ago
ClearPoint Neuro (CLPT) Q3 2026 Earnings Call TranscriptRevenue surged 36% to $12.1 million on IRRAflow integration and record equipment placements.
CATALYSTYahoo • 3d ago
What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings CallClearPoint Neuro (NASDAQ:CLPT) reported third-quarter 2026 revenue growth of 36% as sales increased across its biologics and drug-delivery, neurosurgery navigation and therapy, and capital equipment and software business
RISK WATCHYahoo • 4d ago
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue EstimatesClearPoint Neuro (CLPT) delivered earnings and revenue surprises of +25.00% and -3.40%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
RISK WATCHChartMill • 4d ago
ClearPoint Neuro (NASDAQ:CLPT) Falls 25% as Q3 Revenue Miss Overshadows EPS BeatClearPoint Neuro Q3 revenue missed estimates but EPS beat; margins pressured and shares fell 25% after hours, with 2026 guidance roughly in line.
MARKET WIRESeekingAlpha • 4d ago
ClearPoint Neuro, Inc. (CLPT) Q3 2026 Earnings Call TranscriptClearPoint Neuro, Inc. (CLPT) Q3 2026 Earnings Call October 28, 2026 4:30 PM EDTCompany ParticipantsJoseph Burnett - President, CEO & DirectorDanilo...
CATALYSTYahoo • 4d ago
ClearPoint Neuro Reports Third Quarter 2026 ResultsNeurosurgery Navigation & Therapy Grew 59% to $5.4 MillionSOLANA BEACH, CA / ACCESS Newswire / October 28, 2026 / (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise n
MARKET WIREBenzinga • 4d ago
ClearPoint Neuro Q3 2026 Earnings Call TranscriptClearPoint Neuro (NASDAQ:CLPT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time access to
MARKET WIREBenzinga • 4d ago
ClearPoint Neuro Narrows FY2026 Sales Guidance from $48.000M-$52.000M to $48.000M-$50.000M vs $49.000M EstClearPoint Neuro (NASDAQ:CLPT) narrows FY2026 sales outlook from $48.000 million-$52.000 million to $48.000 million-$50.000 million vs $49.000 million estimate.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLPT)
- ✓Walkthrough of CLPT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CLPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.38%▼ DESCENDING CHANNEL
2026-10-30O $10.69H $10.81L $10.00C $10.69VOL 916.4K
RES: $15.00SUP: $8.84SMA50: $12.51SMA200: $12.96
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CLPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +17.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CLPT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CLPT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CLPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLPT)
Health Care Rank #841 of 1016
⚔️ TMCI vs CLPT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CLPT vs. TMCI, EMBC, MOBI, ANIK)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, ClearPoint Neuro Inc. (CLPT) ranks #841 by composite RQD confidence (34/100, grade E) and #505 by equity capitalization ($342.7M). Within this direct 5-issuer industry benchmark cohort, EMBC leads on earnings valuation at 3.9x trailing P/E, while EMBC leads on capital efficiency and profitability with 35.5% ROIC and 62.6% gross margin. EMBC currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with CLPT at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CLPT
ACTIVE
ClearPoint Neuro Inc. | E | 34/100 | — | 61.4% | -35.0% | +1.23% | $342.7M | Benchmark Subject |
| TMCI Treace Medical Concepts Inc. | D- | 41/100 | — | 79.8% | -32.4% | +4.76% | $329.1M | /tmci-vs-clpt → |
| EMBC Embecta Corp. | B | 74/100 | 3.9x | 62.6% | 35.5% | +1.55% | $371.7M | /embc-vs-clpt → |
| MOBI Mobia Medical Inc. | D | 46/100 | — | — | — | -4.41% | $375.2M | /mobi-vs-clpt → |
| ANIK Anika Therapeutics Inc. | D+ | 55/100 | — | 56.6% | -10.2% | +1.11% | $291.6M | /anik-vs-clpt → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001285550In its most recent audited fiscal period (FY2025, filed 2025-12-31), ClearPoint Neuro Inc. (CLPT) reported GAAP revenue of $37.0M (+17.8% vs. FY2024 revenue of $31.4M , and +54.3% cumulative change since FY2023) , GAAP net income of -$25.5M, operating cash flow of -$23.9M, and free cash flow of -$24.4M (-164.7% YoY). On the balance sheet, CLPT closed FY2025 with $97.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $37.0M | -$25.5M | -$23.9M | -$24.4M | $97.7M | — |
| FY2024 (FY) | 2024-12-31 | $31.4M | -$18.9M | -$8.9M | -$9.2M | $39.2M | — |
| FY2023 (FY) | 2023-12-31 | $24.0M | -$22.1M | -$13.7M | -$13.7M | — | — |
3. CLPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CLPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, ClearPoint Neuro Inc. (NASDAQ: CLPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $10.69 (+1.23% 1D, market cap $342.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLPT ranks #841 in composite RQD confidence.
How does CLPT compare to TMCI and EMBC in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), CLPT carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 61.4%, and ROIC of -35.0%. By comparison, TMCI (Treace Medical Concepts Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -32.4%, cap $329.1M) and EMBC (Embecta Corp.) posts a B grade (74/100 RQD, P/E 3.9x, ROIC 35.5%, cap $371.7M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CLPT?
Per CLPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001285550), ClearPoint Neuro Inc. generated $37.0M in revenue (+17.8% YoY), -$25.5M in net income, and -$24.4M in free cash flow against $97.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CLPT trading relative to its 50-day, 200-day, and 52-week technical levels?
CLPT last traded at $10.69 (+1.23% on volume of 1,252,659 shares), positioning the stock -14.55% below its 50-day simple moving average ($12.51) and -17.52% below its 200-day simple moving average ($12.96). Across its 52-week range of $8.27 to $19.68, CLPT sits at the 21.2% percentile with a 14-day RSI of 48.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.35 to $12.03).
CLPT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CLPT stock moving today?
Why CLPT Stock advanced +1.23% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.